Apogee Therapeutics Statistics Share Statistics Apogee Therapeutics has 59.53M
shares outstanding. The number of shares has increased by 1.79%
in one year.
Shares Outstanding 59.53M Shares Change (YoY) 1.79% Shares Change (QoQ) 0.05% Owned by Institutions (%) 99.99% Shares Floating 48.25M Failed to Deliver (FTD) Shares 2,190 FTD / Avg. Volume 0.24%
Short Selling Information The latest short interest is 9.19M, so 15.76% of the outstanding
shares have been sold short.
Short Interest 9.19M Short % of Shares Out 15.76% Short % of Float 33.57% Short Ratio (days to cover) 5.12
Valuation Ratios PE Ratio 0 Forward PE -6.42 PS Ratio 0 Forward PS n/a PB Ratio 3.49 P/FCF Ratio -14.51 PEG Ratio 0
Financial Ratio History Enterprise Valuation Apogee Therapeutics has an Enterprise Value (EV) of 2.37B.
EV / Sales 0 EV / EBITDA -10.93 EV / EBIT -13.85 EV / FCF -13.75
Financial Position The company has a current ratio of 18.55,
with a Debt / Equity ratio of 0.02.
Current Ratio 18.55 Quick Ratio 18.55 Debt / Equity 0.02 Debt / EBITDA -0.05 Debt / FCF -0.07 Interest Coverage 0
Financial Efficiency Return on Equity is 0% and Return on Invested Capital is 0%.
Return on Equity 0% Return on Assets 0% Return on Invested Capital 0% Revenue Per Employee n/a Profits Per Employee n/a Employee Count 196 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -18K Effective Tax Rate 100%
Stock Price Statistics The stock price has increased by -22.22% in the
last 52 weeks. The beta is 1.44, so Apogee Therapeutics's
price volatility has been higher than the market average.
Beta 1.44 52-Week Price Change -22.22% 50-Day Moving Average 39.88 200-Day Moving Average 41.29 Relative Strength Index (RSI) 37.53 Average Volume (20 Days) 902,219
Income Statement
Revenue n/a Gross Profit n/a Operating Income -216.87M Net Income n/a EBITDA -216.87M EBIT n/a Earnings Per Share (EPS) 0
Full Income Statement Balance Sheet The company has 141.79M in cash and 11.83M in
debt, giving a net cash position of 129.96M.
Cash & Cash Equivalents 141.79M Total Debt 11.83M Net Cash 129.96M Retained Earnings -305.92M Total Assets 714.16M Working Capital 488.57M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -171.17M
and capital expenditures -1.15M, giving a free cash flow of -172.33M.
Operating Cash Flow -171.17M Capital Expenditures -1.15M Free Cash Flow -172.33M FCF Per Share -3.12
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
